HSBC Holdings
ASBP

HSBC Holdings’s Aspire Biopharma ASBP Stock Holding History

HSBC Holdings’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-965
Closed -$12.2M – 2783
2023
Q1 		$12.2M Buy
965
+7
+0.7% +$87.5K 0.01% 778
2022
Q4 		$11.9M Hold
958
– – 0.01% 864
2022
Q3 		$11.7M Hold
958
– – 0.02% 781
2022
Q2 		$11.5M Buy
+958
New +$11.5M 0.02% 816

Other funds holding ASBP

PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
PSAMP
P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
AI
Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
ETH
Exos TFP Holdings New York $162M AUM 16.08% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

HSBC Holdings's ASBP Position: Q2 2023 in Review

HSBC Holdings sold out of Aspire Biopharma (ASBP) in Q2 2023, closing a stake of 965 shares — an estimated $12.2M sold.

HSBC Holdings first reported a position in ASBP in Q2 2022 and held it in 4 quarters. The position peaked at $12.2M in Q1 2023. 14 funds tracked by Wall St. Rank hold ASBP as of Q2 2023.

  • HSBC Holdings reported no remaining Aspire Biopharma position as of Q2 2023 after selling out during the quarter.
  • HSBC Holdings sold 965 Aspire Biopharma shares in Q2 2023, an estimated $12.2M.
  • HSBC Holdings first reported a position in Aspire Biopharma in Q2 2022 and held it in 4 quarters.
  • HSBC Holdings's Aspire Biopharma position peaked at $12.2M in Q1 2023.
  • 14 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2023.

Based on HSBC Holdings's 13F filing for Q2 2023, filed 11 Aug 2023.